AMENDMENTS TO THE CLAIMS

1-19. (Canceled)

20. (Previously Presented) A pharmaceutical composition that elevates a dendritic cell precursor level in the blood, said pharmaceutical composition comprising:

MIP-1α or a functional derivative thereof as the active ingredient; and

a pharmaceutically acceptable carrier.

21. (Previously Presented) The pharmaceutical composition of claim 20, wherein MIP-1α is chemically modified with an amphipathic polymer.

22. (Previously Presented) The pharmaceutical composition of claim 21 or 22, wherein the functional derivative of MIP-1α is BB-10010.

23. (Previously Presented) The pharmaceutical composition of claim 21, wherein the amphipathic polymer is a partially alkyl-esterified styrene-maleic acid copolymer or a polyethylene glycol derivative.

24. (Previously Presented) A method of elevating a dendritic cell precursor level in the blood in a patient in need thereof, said method comprising:

administering an effective amount of MIP-1α or a functional derivative thereof to said patient.

25. (Previously Presented) The method of claim 24, wherein the administered functional derivative of MIP-1α is BB-10010.

26. (Previously Presented) The method of claim 24, wherein the administered functional derivative of MIP-1α is MIP-1α or BB-10010 which is chemically modified with an amphipathic polymer.

27. (Previously Presented) The method of 26, wherein the amphipathic polymer is a partially alkyl-esterified styrene-maleic acid copolymer or a polyethylene glycol derivative.

28. (Previously Presented) A functional derivative of MIP-1α, wherein the amphipathic polymer is a partially alkyl-esterified styrene-maleic acid copolymer or a polyethylene glycol derivative.

29. (New) The method of 26, wherein the amphipathic polymer is a partially alkyl-esterified styrene-maleic acid copolymer.